Literature DB >> 20118395

Chronic heart failure: contemporary diagnosis and management.

Gautam V Ramani1, Patricia A Uber, Mandeep R Mehra.   

Abstract

Chronic heart failure (CHF) remains the only cardiovascular disease with an increasing hospitalization burden and an ongoing drain on health care expenditures. The prevalence of CHF increases with advancing life span, with diastolic heart failure predominating in the elderly population. Primary prevention of coronary artery disease and risk factor management via aggressive blood pressure control are central in preventing new occurrences of left ventricular dysfunction. Optimal therapy for CHF involves identification and correction of potentially reversible precipitants, target-dose titration of medical therapy, and management of hospitalizations for decompensation. The etiological phenotype, absolute decrease in left ventricular ejection fraction and a widening of QRS duration on electrocardiography, is commonly used to identify patients at increased risk of progression of heart failure and sudden death who may benefit from prophylactic implantable cardioverter-defibrillator placement with or without cardiac resynchronization therapy. Patients who transition to advanced stages of disease despite optimal traditional medical and device therapy may be candidates for hemodynamically directed approaches such as a left ventricular assist device; in selected cases, listing for cardiac transplant may be warranted.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118395      PMCID: PMC2813829          DOI: 10.4065/mcp.2009.0494

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  153 in total

1.  A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.

Authors:  Eric J Eichhorn; Michael J Domanski; Heidi Krause-Steinrauf; Michael R Bristow; Philip W Lavori
Journal:  N Engl J Med       Date:  2001-05-31       Impact factor: 91.245

Review 2.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension.

Authors:  Arnfried U Klingbeil; Markus Schneider; Peter Martus; Franz H Messerli; Roland E Schmieder
Journal:  Am J Med       Date:  2003-07       Impact factor: 4.965

3.  Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss.

Authors:  M A Alpert; B E Terry; M Mulekar; M V Cohen; C V Massey; T M Fan; H Panayiotou; V Mukerji
Journal:  Am J Cardiol       Date:  1997-09-15       Impact factor: 2.778

Review 4.  Digoxin. A neurohormonal modulator in heart failure?

Authors:  M Gheorghiade; D Ferguson
Journal:  Circulation       Date:  1991-11       Impact factor: 29.690

5.  Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion.

Authors:  T P Dormans; J J van Meyel; P G Gerlag; Y Tan; F G Russel; P Smits
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

6.  Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group.

Authors:  J N Cohn; S Ziesche; R Smith; I Anand; W B Dunkman; H Loeb; G Cintron; W Boden; L Baruch; P Rochin; L Loss
Journal:  Circulation       Date:  1997-08-05       Impact factor: 29.690

7.  Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group.

Authors:  M Packer; C M O'Connor; J K Ghali; M L Pressler; P E Carson; R N Belkin; A B Miller; G W Neuberg; D Frid; J H Wertheimer; A B Cropp; D L DeMets
Journal:  N Engl J Med       Date:  1996-10-10       Impact factor: 91.245

8.  The epidemiology of heart failure: the Framingham Study.

Authors:  K K Ho; J L Pinsky; W B Kannel; D Levy
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

9.  The progressive cardiorenal syndrome in heart failure: mechanisms and therapeutic insights.

Authors:  Jennifer R Brown; Patricia A Uber; Mandeep R Mehra
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-08

10.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

View more
  63 in total

1.  Risk of heart failure among postmenopausal women: a secondary analysis of the randomized trial of vitamin D plus calcium of the women's health initiative.

Authors:  Macarius M Donneyong; Carlton A Hornung; Kira C Taylor; Richard N Baumgartner; John A Myers; Charles B Eaton; Eiran Z Gorodeski; Liviu Klein; Lisa W Martin; James M Shikany; Yiqing Song; Wenjun Li; JoAnn E Manson
Journal:  Circ Heart Fail       Date:  2014-11-14       Impact factor: 8.790

2.  95-year-old woman with sudden-onset dyspnea.

Authors:  Muaz M Abudiab; Olufunso W Odunukan; William K Freeman
Journal:  Mayo Clin Proc       Date:  2012-06       Impact factor: 7.616

3.  Does thermal therapy benefit patients with chronic heart failure?

Authors:  J Timothy Hanlon
Journal:  Mayo Clin Proc       Date:  2010-07       Impact factor: 7.616

Review 4.  Contemporary strategies in the diagnosis and management of heart failure.

Authors:  Shannon M Dunlay; Naveen L Pereira; Sudhir S Kushwaha
Journal:  Mayo Clin Proc       Date:  2014-03-29       Impact factor: 7.616

Review 5.  Point-of-care ultrasound education to improve care of dialysis patients.

Authors:  Surekha Mullangi; Stephen M Sozio; Paul Segal; Steven Menez; Carol Martire; Tariq Shafi
Journal:  Semin Dial       Date:  2018-01-03       Impact factor: 3.455

6.  β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction.

Authors:  Richard Carr; Justin Schilling; Jianliang Song; Rhonda L Carter; Yang Du; Sungsoo M Yoo; Christopher J Traynham; Walter J Koch; Joseph Y Cheung; Douglas G Tilley; Jeffrey L Benovic
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-27       Impact factor: 11.205

7.  More help for patients with less severe heart failure.

Authors:  Kelly Bossenbroek; Anne L Mounsey
Journal:  J Fam Pract       Date:  2011-08       Impact factor: 0.493

Review 8.  Targeted gene therapy for the treatment of heart failure.

Authors:  Kleopatra Rapti; Antoine H Chaanine; Roger J Hajjar
Journal:  Can J Cardiol       Date:  2011 May-Jun       Impact factor: 5.223

9.  Psychometrics of the Zarit Burden Interview in Caregivers of Patients With Heart Failure.

Authors:  Sami Y Al-Rawashdeh; Terry A Lennie; Misook L Chung
Journal:  J Cardiovasc Nurs       Date:  2016 Nov/Dec       Impact factor: 2.083

10.  Development of a Double-Lumen Cannula for a Percutaneous RVAD.

Authors:  Dongfang Wang; Cameron Jones; Cherry Ballard-Croft; Ju Zhao; Guangfeng Zhao; Stephen Topaz; Joseph B Zwischenberger
Journal:  ASAIO J       Date:  2015 Jul-Aug       Impact factor: 2.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.